Health-related quality of life and economic burden in patients with restless legs syndrome (Q37763140)

22 August 2017

Health-related quality of life and economic burden in patients with restless legs syndrome (English)

1 reference

22 August 2017

1 reference

Karin Stiasny-Kolster

series ordinal

2

object named as

Karin Stiasny-Kolster

1 reference

22 August 2017

3

Wolfgang H Oertel

1 reference

22 August 2017

4

Richard C Dodel

1 reference

22 August 2017

Jens P Reese

1

1 reference

22 August 2017

1 October 2007

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

5

1 reference

22 August 2017

503-521

1 reference

Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome

22 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Validation of the Johns Hopkins restless legs severity scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Costs and quality of life of patients with multiple sclerosis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

EEG mapping in patients with restless legs syndrome as compared with normal controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

The Spanish version of the quality of life index: presentation and validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Efficacy and safety of pramipexole in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Evaluating the quality of life of patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Restless legs syndrome prevalence and impact: REST general population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Screening for sleep disorders in community pharmacies--evaluation of a campaign in Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Restless legs syndrome: a community-based study of prevalence, severity, and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Epidemiology of restless legs in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Epidemiology of restless legs syndrome as diagnosed in UK primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Restless legs syndrome symptoms in primary care: a prevalence study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Epidemiology of restless legs symptoms in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Prevalence of restless legs syndrome and periodic limb movement disorder in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Burden of restless legs syndrome on health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Sex and the risk of restless legs syndrome in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Long-term effects of pergolide in the treatment of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

A randomized controlled study of pergolide in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

Restless legs syndrome: Epidemiological and clinicogenetic study in a South Tyrolean population isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.5.503

21 January 2018

Identifiers

DOI

10.1586/14737167.7.5.503

1 reference

22 August 2017

1 reference

PubMed ID

20528395